Trial Spotlight

FORAGER-1; NCT05614739

A Phase 1, Open-label, Multicenter Study of LY3866288 (LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations^a

See Trial

Trial Spotlight

NCT06400472

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α, in Participants With Selected Advanced Solid Tumors^a

See Trial

Trial Spotlight

SUNRAY-01; NCT06119581

A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression^a

See Trial

Trial Spotlight

NCT06607185

A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors^a

See Trial

Trial Spotlight

NCT06561685

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2 (BRM) Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4 (BRG1) Alterations^a

See Trial

FORAGER-1; NCT05614739

NCT06400472

SUNRAY-01; NCT06119581

NCT06607185

NCT06561685

Filter our pipeline to find information relevant to you. Search results will appear below.

Other Solid Tumors